Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
Urosevic
V
V
Chollet
P
P
Adenis
A
A
Chauvergne
J
J
Fargeot
P
P
Roche
H
H
Kerbrat
P
P
Lentz
M A
MA
Fumoleau
P
P
Chevallier
B
B
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000191:economics; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea